ICYMI: Pharmacokinetic Study Begins for GTX-102 for Ataxia-Telangiectasia
In mid-September 2022, specialty pharmaceutical company Acasti Pharma Inc. (“Acasti”) shared via a news release that it had initiated a pharmacokinetic study on GTX-102. Within the study, Acasti hopes…